Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Key claim: A Phase 2 expansion trial is evaluating whether ruxolitinib can improve outcomes in patients with chronic myelomonocytic leukemia (CMML).
Abstract
This study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug (ruxolitinib) can improve outcomes of patients with CMML.
Why this matters
Ruxolitinib is a JAK1/2 inhibitor foundational to myelofibrosis therapy, and its Phase 2 expansion into CMML tests whether JAK-STAT blockade — already implicated in CMML inflammatory biology and being probed via pacritinib vs hydroxyurea in proliferative CMML — can improve outcomes in an MDS/MPN overlap disease with limited approved options. This adds subtype-specific evidence on repurposing an established MPN JAK inhibitor into CMML and helps delineate whether JAK inhibition benefits track with the proliferative phenotype or extend more broadly across CMML.